5d 1m 3m 1y 5y 10y
Veracyte Updates Presentation Date and Time at the Cowen and Company 34th Annual Health Care ConferencePR Newswire (Mar 3, 2014)
PR Newswire (Feb 26, 2014)
PR Newswire (Feb 5, 2014)
VCYT vs. ETF Alternatives
Tuesday, Mar 184:28 PM
Tuesday, Nov 262013, 12:48 PM
Tuesday, Nov 262013, 12:48 PM| 1 Comment
- Galena Biopharma (GALE +6.8%) initiated at Outperform at Oppenheimer. Price target is $6.
- Veracyte (VCYT +7%) started at Outperform at Leerink (PT $17), William Blair, and Cowen (PT $16).
- Surgical Care Affiliates (SCAI +2.8%) initiated at Buy at BofA. Price target is $34. Yesterday: Goldman starts SCAI at Neutral.
- Heartware (HTWR +2.3%) started at Buy at CRT Capital. Price target is $109.
- Mallinckrodt (MNK +2%) initiated at Buy at Jefferies. Price target is $60.
- Harvard Bioscience (HBIO +4.4%) upgraded to Buy from Neutral at Sidoti.
- Forest Labs (FRX +1.1%) upgraded to Neutral from Underweight at Piper. Price target hiked to $49 from $33.
- Cardiovascular Systems (CSII +0.9%) cut to Hold at Benchmark. Price target is $35.
Tuesday, Nov 262013, 9:52 AM
Tuesday, Nov 262013, 9:52 AM| Comment!
- Veracyte (VCYT +10.3%) shares jump after Leerink (PT of $17), Cowen (PT of $16), and William Blair (previous) initiate the stock at Outperform. Morgan Stanley, the last of the 4 underwriters, has not yet issued a rating.
- Leerink Swann analyst Dan Leonard observes "several upcoming catalysts should drive outperformance of VCYT's stock over the next 12 months, including: (1) continued physician adoption of its Afirma test to help resolve indeterminate thyroid nodules, (2) additional guideline endorsement and reimbursement coverage for Afirma, (3) launch of the Afirma malignant test (2Q:14), and (4) presentation of lung data in 2014."
Tuesday, Nov 262013, 7:41 AM|Tuesday, Nov 262013, 7:41 AM| Comment!
Monday, Nov 252013, 6:54 PM
We currently have no instablog posts on this stock.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.